| [1] |
Xie YH, Gao QY, Cai GX, et al. Fecal clostridium symbiosum for noninvasive detection of early and advanced colorectal cancer: test and validation studies[J]. EBio Medicine, 2017, 25:32-40.
|
| [2] |
Saus E, Iraola-Guzmán S, Willis JR, et al. Microbiome and colorectal cancer: Roles in carcinogenesis and clinical potential[J]. Mol Aspects Med, 2019, 69:93-106.
doi: 10.1016/j.mam.2019.05.001
URL
|
| [3] |
Mizutani S, Yamada T, Yachida S. Significance of the gut microbiome in multistep colorectal carcinogenesis[J]. Cancer Sci, 2020, 111(3):766-773.
doi: 10.1111/cas.14298
URL
|
| [4] |
Brennan CA, Garrett WS. Fusobacterium nucleatum - symbiont, opportunist and oncobacterium[J]. Nat Rev Microbiol, 2019, 17(3):156-166.
doi: 10.1038/s41579-018-0129-6
URL
|
| [5] |
Hamada T, Zhang X, Mima K, et al. Fusobacterium nucleatum in colorectal cancer relates to immune response differentially by tumor microsatellite instability status[J]. Cancer Immunol Res, 2018, 6(11):1327-1336.
doi: 10.1158/2326-6066.CIR-18-0174
URL
|
| [6] |
Pleguezuelos-Manzano C, Puschhof J, Huber AR, et al. Mutational signature in colorectal cancer caused by genotoxic pks+ E. coli[J]. Nature, 2020-02-27.[Epub ahead of print]
|
| [7] |
Palmgren Colov E, Helene Degett T, Raskov H, et al. The impact of the gut microbiota on prognosis after surgery for colorectal cancer - a systematic review and meta-analysis[J]. APMIS, 2020-02-04.[Epub ahead of print]
|
| [8] |
Yamaoka Y, Suehiro Y, Hashimoto S, et al. Fusobacterium nucleatum as a prognostic marker of colorectal cancer in a Japanese population[J]. J Gastroenterol, 2018, 53(4):517-524.
doi: 10.1007/s00535-017-1382-6
pmid: 28823057
|
| [9] |
Yu T, Guo F, Yu Y, et al. Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy[J]. Cell, 2017, 170(3):548-563,e16.
doi: 10.1016/j.cell.2017.07.008
URL
|
| [10] |
Wei Z, Cao S, Liu S, et al. Could gut microbiota serve as prognostic biomarker associated with colorectal cancer patients' survival? A pilot study on relevant mechanism[J]. Oncotarget, 2016, 7(29):46158-46172.
doi: 10.18632/oncotarget.10064
URL
|
| [11] |
Selby K, Levine EH, Doan C, et al. Effect of sex, age, and positivity threshold on fecal immunochemical test accuracy: a systematic review and meta-analysis[J]. Gastroenterology, 2019, 157(6):1494-1505.
doi: 10.1053/j.gastro.2019.08.023
URL
|
| [12] |
Bosch LJW, Melotte V, Mongera S, et al. Multitarget stool DNA test performance in an average-risk colorectal cancer screening population[J]. Am J Gastroenterol, 2019, 114(12):1909-1918.
doi: 10.14309/ajg.0000000000000445
pmid: 31764091
|
| [13] |
Zhang X, Zhu X, Cao Y, et al. Fecal fusobacterium nucleatum for the diagnosis of colorectal tumor: A systema-tic review and meta-analysis[J]. Cancer Med, 2019, 8(2):480-491.
doi: 10.1002/cam4.1850
URL
|
| [14] |
Guo S, Li L, Xu B, et al. A simple and novel fecal biomarker for colorectal cancer: ratio of fusobacterium nucleatum to probiotics populations, based on their antagonistic effect[J]. Clin Chem, 2018, 64(9):1327-1337.
doi: 10.1373/clinchem.2018.289728
URL
|
| [15] |
Yang J, Li D, Yang Z, et al. Establishing high-accuracy biomarkers for colorectal cancer by comparing fecal microbiomes in patients with healthy families[J]. Gut Microbes, 2020-01-23.[Epub ahead of print]
|
| [16] |
Coker OO, Nakatsu G, Dai RZ, et al. Enteric fungal microbiota dysbiosis and ecological alterations in colorectal cancer[J]. Gut, 2019, 68(4):654-662.
doi: 10.1136/gutjnl-2018-317178
URL
|
| [17] |
Nakatsu G, Zhou H, Wu WKK, et al. Alterations in enteric virome are associated with colorectal cancer and survival outcomes[J]. Gastroenterology, 2018, 155(2):529-541,e5.
doi: S0016-5085(18)30479-7
pmid: 29689266
|
| [18] |
Liang Q, Chiu J, Chen Y, et al. Fecal bacteria act as novel biomarkers for noninvasive diagnosis of colorectal cancer[J]. Clin Cancer Res, 2017, 23(8):2061-2070.
doi: 10.1158/1078-0432.CCR-16-1599
URL
|
| [19] |
Yu J, Feng Q, Wong SH, et al. Metagenomic analysis of faecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer[J]. Gut, 2017, 66(1):70-78.
doi: 10.1136/gutjnl-2015-309800
URL
|
| [20] |
Thomas AM, Manghi P, Asnicar F, et al. Metagenomic analysis of colorectal cancer datasets identifies cross-cohort microbial diagnostic signatures and a link with choline degradation[J]. Nat Med, 2019, 25(4):667-678.
doi: 10.1038/s41591-019-0405-7
URL
|
| [21] |
Zhang J, Haines C, Watson AJM, et al. Oral antibiotic use and risk of colorectal cancer in the United Kingdom, 1989-2012: a matched case-control study[J]. Gut, 2019, 68(11):1971-1978.
doi: 10.1136/gutjnl-2019-318593
URL
|
| [22] |
Ou J, Carbonero F, Zoetendal EG, et al. Diet, microbiota, and microbial metabolites in colon cancer risk in rural Africans and African Americans[J]. Am J Clin Nutr, 2013, 98(1):111-120.
doi: 10.3945/ajcn.112.056689
URL
|
| [23] |
Mehta RS, Nishihara R, Cao Y, et al. Association of die-tary patterns with risk of colorectal cancer subtypes classified by fusobacterium nucleatum in tumor tissue[J]. JAMA Oncol, 2017, 3(7):921-927.
doi: 10.1001/jamaoncol.2016.6374
pmid: 28125762
|
| [24] |
Cruz BCS, Sarandy MM, Messias AC, et al. Preclinical and clinical relevance of probiotics and synbiotics in co-lorectal carcinogenesis: a systematic review[J]. Nutr Rev, 2020,pii:nuz087.
|
| [25] |
Chang CW, Liu CY, Lee HC, et al. Lactobacillus casei variety rhamnosus probiotic preventively attenuates 5-fluo-rouracil/oxaliplatin-induced intestinal injury in a syngeneic colorectal cancer model[J]. Front Microbiol, 2018, 9:983.
doi: 10.3389/fmicb.2018.00983
URL
|
| [26] |
Wang ZH, Liu JM, Li CY, et al. Bacterial biofilm bioinspired persistent luminescence nanoparticles with gut-oriented drug delivery for colorectal cancer imaging and chemotherapy[J]. ACS Appl Mater Interfaces, 2019, 11(40):36409-36419.
doi: 10.1021/acsami.9b12853
URL
|
| [27] |
Zheng DW, Dong X, Pan P, et al. Phage-guided modulation of the gut microbiota of mouse models of colorectal cancer augments their responses to chemotherapy[J]. Nat Biomed Eng, 2019, 3(9):717-728.
doi: 10.1038/s41551-019-0423-2
URL
|
| [28] |
Darbandi A, Mirshekar M, Shariati A, et al. The effects of probiotics on reducing the colorectal cancer surgery complications: A periodic review during 2007-2017[J]. Clin Nutr, 2019,pii: S0261-5614(19)33135-33138.
|
| [29] |
Zitvogel L, Ma Y, Raoult D, et al. The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies[J]. Science, 2018, 359(6382):1366-1370.
doi: 10.1126/science.aar6918
URL
|
| [30] |
Wang Y, Wiesnoski DH, Helmink BA, et al. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis[J]. Nat Med, 2018, 24(12):1804-1808.
doi: 10.1038/s41591-018-0238-9
URL
|
| [31] |
Mima K, Nishihara R, Qian ZR, et al. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis[J]. Gut, 2016, 65(12):1973-1980.
doi: 10.1136/gutjnl-2015-310101
URL
|
)
